Diagnostic pitfalls of nonsecretory myeloma manifesting as multiple foci of periosseous plasmacytomas  by Chen, Ling-Ping et al.
Available online at www.sciencedirect.comJournal of the Chinese Medical Association 74 (2011) 464e468
www.jcma-online.comCase Report
Diagnostic pitfalls of nonsecretory myeloma manifesting as multiple foci of
periosseous plasmacytomas
Ling-Ping Chen a,d,*, Tsung-Ho Sun a,d, Pin-Pen Hsieh c,d, Ling-Jung Yen b,d,
Shyh-Jer Lin a,d, Ming-Sun Yu a,d
aDivision of Hematology and Oncology, Kaohsiung Veterans General Hospital, Kaohsiung, Taiwan, ROC
bDivision of Allergy, Immunology, and Rheumatology, Department of Internal Medicine, Kaohsiung Veterans General Hospital, Kaohsiung, Taiwan, ROC
cDepartment of Pathology and Laboratory Medicine, Kaohsiung Veterans General Hospital, Kaohsiung, Taiwan, ROC
d School of Medicine, National Yang-Ming University, Taipei, Taiwan, ROC
Received March 16, 2010; accepted December 9, 2010AbstractNonsecretory myeloma, which comprises 1e5% of all myelomas, is a variant of plasma cell myeloma. It is defined as symptomatic myeloma
without detectable monoclonal immunoglobulin levels on serum or urine immunofixation electrophoresis. Here, we report two cases of non-
secretory plasma cell myeloma that manifested as multi-foci periosseous plasmacytomas. Due to the inability to detect monoclonal immuno-
globulin on serum or urine immunofixation electrophoresis and the lack of evidence of clonal plasma cells in the bone marrow, it was difficult to
establish an early, accurate diagnosis. Misdiagnosing or mislabeling symptomatic myeloma patients with plasmacytoma results in the delay of
their systemic treatment. Therefore, comprehensive imaging studies, the detection of free light chains, and histopathological confirmation from
different sites and time points are necessary.
Copyright  2011 Elsevier Taiwan LLC and the Chinese Medical Association. All rights reserved.
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According to the World Health Organization (WHO) clas-
sification system, the diagnosis of symptomatic myeloma is
based on the pathological proof of plasmacytoma or the
presence of bone marrow clonal plasma cells and end-organ
damage, such as anemia, hypercalcemia, lytic bone lesions,
renal insufficiency, hyperviscosity, amyloidosis, or recurrent
infections. For patients that fulfill the above criteria,
a minimum level of monoclonal proteins (M-protein) or
percentage of bone marrow plasma cells is no longer neces-
sary. Symptomatic myeloma without detectable monoclonal
immunoglobulin (Ig) levels on serum or urine immunofixation* Corresponding author. Dr. Ling-Ping Chen, Division of Hematology and
Oncology, Department of Internal Medicine, Kaohsiung Veterans General
Hospital, 386, Ta-Chung lst Road, Kaohsiung 813, Taiwan, ROC.
E-mail address: xguaalu@yahoo.com.tw (L.-P. Chen).
1726-4901/$ - see front matter Copyright  2011 Elsevier Taiwan LLC and the C
doi:10.1016/j.jcma.2011.08.018electrophoresis characterizes nonsecretory myeloma by the
WHO definition. This diagnosis constitutes 1e5% of all
myeloma patients.1 By immunohistochemical analysis, 85% of
patients with cytoplasmic M-protein are nonsecretors and the
other 15% are nonproducers. Meanwhile, the detection of free
light chains (FLC) has made true nonproducers even rarer than
before.2 The proposed pathophysiology includes the dimin-
ished capacity to synthesize immunoglobulins, defects in
secretion, and the rapid degradation of intracellular immuno-
globulins.3 The manifestations of nonsecretory myeloma are
similar to those of the secretory types, with the exceptions of
improved hemoglobin levels, a less aggressive clinical
evolution, lower incidences of renal insufficiency and hyper-
calcemia, improved Ig levels, and the decreased occurrence
osteolytic lesions.4 The survival outcomes of nonsecretory
myeloma patients are comparable to secretors.5 However,
because uneven distribution and slow infiltration are not
unusual in patients with myeloma, periosseous plasmacytomashinese Medical Association. All rights reserved.
Table 1
Serological parameters used in the diagnoses of the two reported cases.
Parameters Reference range Case 1 Case 2
Hemoglobin 13.5e17.8 g/dL 13.8 14.6
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The pitfalls of misdiagnosing nonsecretory myeloma with the
manifestations of multi-foci periosseous plasmacytomas are
further discussed.Creatine 0.7e1.5 mg/dL 1.1 1.1
Total protein 6.4e8.4 g/dL 6.5 d
Globulin 2.3e3.5 gm/dL 2.7 d2. Case Report
Calcium 8.4e10.6 mg/dL 9.3 9.6
IgG 751e560 mg/dL 1330 1030.02.1. Case 1
IgA 82e453 mg/dL 445 287.0
IgM 46e304 mg/dL 45.5* 115.0
Kappa light chain 542e248 mg/dL 874 1000
Lambda light chain 293e725 mg/dL 382 404
Serum free light-chain ratio 0.26e1.65 2.29* 2.47*
Beta2-microglobulin 670e1310 mg/L 1457* 956.1
* abnormal data.An 84-year-old man had been previously diagnosed with
diabetes mellitus, hypertension, and chronic obstructive
pulmonary disease several years prior. He visited our ortho-
pedic outpatient department complaining of painful swelling
of his right forearm. Radiography showed a pathological
fracture and an osteolytic lesion measuring 2 cm in diameter
on the right distal radius (Fig. 1A). Further studies were
conducted because malignancy was highly suspected.
Computed tomography (CT) of the abdomen revealed lytic
bone lesions with multiple foci. A whole-body bone scan
demonstrated abnormal uptake into the thoracic spine at the
T8, T11, and T12 vertebral bodies, the lumbar spine at the L1,
L2, and L3 vertebral bodies, the left acetabulum, and the left
posterior 11th rib and suspicious focal uptake into the anterior
surface of the sacrum. Magnetic resonance imaging (MRI)
revealed a bulging soft-tissue mass, measuring approximately
18 mm in size, with central necrosis and a pathological frac-
ture in the right distal radial shaft. A CT scan of the chest
showed multiple osteolytic lesions on the T-spine without any
suspicious lung masses. The patient’s tumor markers were all
within normal limits. The patient received curettage of the
tumor mass and open reduction and internal fixation surgery.
Pathological examination of the tumor demonstrated diffuseFig. 1. Images of case 1. (A) One pure osteolytic lesion is clearly visible at the rig
magnetic resonance image of lumbar spine reveals discrete lesions at the T11, T1infiltration of large neoplastic cells with eccentric nuclei and
prominent nucleoli. Immunohistochemical studies were posi-
tive for vimentin and CD138, focally positive for CD56, and
negative for leukocyte common antigen, CD3, CD20, S100,
and cytokeratin. Based on these results, plasma cell disorder
was suspected and further studies were performed. The
patient’s laboratory data are summarized in Table 1. A low
IgM level (45.5 mg/dL; reference range: 46e304 mg/dL),
a high serum free light chain ratio (2.29; reference range:
0.26e1.65), and a high beta2-microglobulin level (1457 mg/L;
reference range: 670e1310 mg/L) were noted as abnormal
findings. However, M-proteins were not detected on serum or
urine protein immunofixation electrophoresis. A bone marrow
biopsy from the bilateral posterior superior iliac crests showed
no evidence of clonal plasma cells. In order to reconfirm these
results, a CT-guided biopsy of the mass lesion at the L3
vertebral body was performed, and the pathological resultsht distal radius with a pathologic fracture (black arrow) (plain film). (B) The
2, L2 and L3 vertebral bodies, as indicated by the white arrows.
Fig. 2. In case 1, the L3-mass demonstrates diffuse immature plasma cells with
enlarged eccentric nucleoli. Kappa immunostaining shows a dot-like cyto-
plasmic staining pattern, as indicated by the black arrow. (400magnification).
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with frequent conspicuous nucleoli that were positive for
CD138 staining and negative for CD3 and CD20 immuno-
staining. The tumor showed kappa light chain restriction and
a single-dot cytoplasmic staining pattern (Fig. 2), which are
consistent with plasmacytoma. Also, MRI of the lumbar spine
revealed several noncontiguous bone lesions on the T7, T11,
T12, L2, and L3 vertebrae and the left iliac bone (Fig. 1B).
Based on these findings, systemic chemotherapy with
melphalan and prednisolone was prescribed to this patient.2.2. Case 2A 32-year-old man was healthy until two months prior to
admission. He found a painful mass over his anterior sternum.
He visited another hospital where a chest CT scan identified
a tumor arising from the distal sternum, but a definite diagnosisFig. 3. Images of case 2. Positron emission tomography-computed tomography
[Maximal Standard Uptake Value, 7.4] and (B) the lateral right 4th rib [Maximal Scould not be made. Therefore, he was admitted to our hospital
for additional examinations. A bone scan identified a single
osteolytic lesion on the distal sternal body. All of the patient’s
tumor markers were within normal range. A tiny hepatic
hemangioma was observed on abdominal CT. He received
a CT-guided biopsy of the sternal mass, and the pathological
results showed malignant cells that were positive for synapto-
physin, focally positive for cytokeratin, and negative for
leukocyte common antigen, chromogranin, and CD5. These
tumor cells were also positive for CD138 on polyclonal kappa
and lambda immunostaining. The initial diagnosis indicated
either a malignant neuroendocrine tumor or plasmacytoma. For
further confirmation, the laboratory data were checked, as
shown in Table 1. A high serum free light chain ratio (2.47;
reference range: 0.26e1.65) was revealed. Later, an open
biopsy was performed. The pathological results demonstrated
diffuse tumor cells with prominent nucleoli; plasmablast was
considered the most likely diagnosis by the morphological
results alone. Immunostaining was positive for vimentin and
negative for CD20, CD3, PAX-5, CD30, synaptophysin, CD56,
S-100, and actin. The patient was focally positive for CD138
and kappa immunostaining, but the lambda staining was
negative. The initial false positive results for synaptophysin
and lambda immunostaining might have been caused by
overstaining the initial, small specimens. Furthermore, the
possibility of a neuroendocrine tumor was excluded by
a negative CD56 stain. However, neither serum nor urine
immunofixation electrophoresis identified a monoclonal band
or clonal plasma cells infiltrating the bone marrow. Finally,
a positron emission tomography (PET)-CT scan demonstrated
fluorodeoxyglucose (FDG)-avid lesions on the sternal body and
the right 4th rib (Fig. 3). The right rib lesion had never been
identified in the previous bone scan or chest CT. Due to the
diagnosis of nonsecretory myeloma, no additional invasive
procedures were arranged for diagnosing the right rib lesion.
Later, the patient received systemic treatment with thalidomide
and dexamethasone instead of curative radiotherapy.scan demonstrating fluorodeoxyglucose-avid lesions in (A) the sternal body
tandard Uptake Value, 15.2].
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In the largest study on periosseous plasmacytomas per-
formed by the Surveillance, Epidemiology, and End-Results
(SEER) program of the National Cancer Institute, only
2.1% of patients (24 of 1164 persons) presented with more
than two lesions from 1973e2005. Patients with more than
two lesions had significantly lower 5-year survival rates than
those with a single lesion (36% vs. 59%; p ¼ 0.032).6 The
diagnosis of multiple plasmacytomas in soft tissues is
acceptable, and local treatment with radiation or a separate
excision is usually adequate. However, multi-foci periosseous
plasmacytoma is regarded as an uncommon presentation of
symptomatic myeloma because myelomas tend to infiltrate
slowly and are sometimes unevenly distributed. The treatment
for myeloma follows the policy of watching and waiting for
indolent nature. Systemic immunochemotherapy is reserved
for symptomatic myeloma patients; radiotherapy generally
only plays a palliative role. Furthermore, misdiagnosing
symptomatic myeloma patients with plasmacytoma might
delay their frontline systemic treatments. However, the line
between asymptomatic and symptomatic myeloma is some-
times blurred, and therefore the limitations of diagnostic tools
must be considered.
By definition, the diagnosis of solitary plasmacytoma of the
bone is based on excluding other lesions by MRI of the axial
skeleton.7 However, a PET scan of the whole body has the
highest sensitivity.8 The sensitivity of PET, MRI, CT, and plain
film scans are 86.3%, 83.3%, 70.4%, and 47.4%, respectively.9
PET, MRI, and CT scans are optional for determining
myeloma, as recommended by the National Comprehensive
Cancer Network Guidelines. Although PET imaging was not
recommended for routine usage by the International Myeloma
Working Group (IMWG) in 2009,10 it is still a unique tool for
the evaluation of nonsecretory myeloma, as shown by case 2 of
this study.11 When cost efficiency is a consideration, MRI
seems the most appropriate for diagnosing patients suspected
of having nonsecretory myeloma. However, PET is still helpful
in some circumstances, such as when negative or equivocal
findings are found on an MRI screening. Whenever plasma-
cytoma is confirmed by histology, either the periosseous or soft
tissue variety, or whenever M-proteins are detected, an exam-
ination of the other lesions present is necessary. MRI or
PET-CT scans are strongly recommended.
The sensitivity levels for protein electrophoresis are about
1e2 g/L, 150e500 mg/L for immunofixation electrophoresis,
and less than 1 mg/L for serum FLC immunoassays.12
Because high levels are often detected on serum FLC in
two-thirds of nonsecretory myeloma patients, in addition to
extreme FLC ratios, true nonsecretors are very rare and the
term “hyposecretors” might be more a suitable descriptor.13
Serum FLC analysis is recommended for making the diag-
nosis of nonsecretory myeloma, accessing prognosis, and
monitoring a patient’s response to treatment, as recommended
by IMWG.14e16 The patients described here were both
hyposecretors with abnormally high FLC ratios, which is
compatible with the clonal kappa plasma cells that were foundon immunostaining. In case 1, the low IgM level is indicative
of clonal plasma disorder.
Plasma cell myeloma usually involves bones that show
active bone marrow hematopoiesis, such as the vertebrae, ribs,
skull, and pelvis. The posterior superior iliac crest is the most
common site for bone marrow studies, and unilateral biopsy is
usually adequate for homogenous infiltration. These two cases
described here presented with multi-focal lesions, but there
was no evidence of involvement of the bilateral iliac crest. In
addition to providing evidence of infiltration into the soft
tissue, pathological specimens are also important for differ-
entiating the subtypes of nonsecretory myeloma by immuno-
histochemical staining, flow cytometry, immunofluorescence,
or electron microscopy.17 In case 1, immunostaining demon-
strated dot-like cytoplasmic staining of the kappa light chain.
The intracellular aggregation of nonsecreted immunoglobulins
is possibly due to the involvement of Russell bodies, which
are derived from disruption of the endoplasmic reticulum-
associated degradation pathway.3 In a previous study, a high
percentage of t(11;14) in nonsecretory myeloma was reported.17
However, because cytogenetic studies were unavailable in our
hospital (including fluorescence in situ hybridization), we have
no information about the cytogenetic statuses of these two
patients.
Furthermore, accurate staging is important for prognosis.
The staging systems for myeloma include the Durie-Salmon
staging system (DSS), the revised Durie-Salmon Plus staging
system (DSS-plus), and the International Staging system
(ISS).9 Most end-organ functions are evaluated under the DSS
system, which classifies patients with solitary bone lesion as
stage 1 and advanced lytic bone lesions as stage 3. The revised
DSS-plus takes the results of MRI and/or PET scans into
account. Stages 1, 2, and 3 indicate that patients have less than
5, 5e20, or more than 20 focal lesions, respectively, and the
assigned stage is in direct proportion to the tumor burden
carried by the patient. The ISS is based on serum beta-2
microglobulin and albumin levels. Thirty-six percent of
patients are classified as different stages when evaluated using
different classification systems.18 Both of the patients reported
here were ISS stage 1; however, case 1 was classified as stage
3A and stage 2A by DSS and DSS-plus, respectively and case
2 was classified as stage 2A and stage 1A by DSS and DSS-
plus, respectively. Because nonsecretory myeloma tends to
be less involved serologically, ISS played a limited role in the
diagnosis of these patients.
In conclusion, misdiagnosing or mislabeling symptomatic
myeloma patients with plasmacytoma might delay their
systemic treatment. Comprehensive image studies, the detec-
tion of free light chains, and histopathological confirmation at
different sites and time points are necessary for diagnosing
patients suspected of having plasmacytoma, especially those
believed to have the nonsecretory variant.
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